6th Annual MarketsandMarkets

Next Gen Immuno-Oncology Congress- UK

10th - 11th March 2022

ILEC Conference Center and IBIS London Earls Court, 47 Lillie Road, London, SW6 1UD

The treatment options for cancer, such as chemotherapies and radiation therapy, although have more side effects, are more widely used as compared to immunotherapies. The former are all based on destroying cancer cells by irradiation, chemotherapy, or surgery. While they can effectively kill or remove cancer cells, the use of these treatments is often limited because they tend to destroy healthy cells in large numbers as well. As immunotherapies involve the mechanism of enhancing the body’s own immunity using man-made proteins such as monoclonal antibodies, they are accepted worldwide over other treatment options.

Our 6th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress to be held on 10th-11th March 2022 in London, UK would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors. This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.

WHAT TO EXPECT

  • Updates in development of ADC’s and Bispecific Ab’s
  • Immune Checkpoint Inhibitors and Combinations
  • Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators)
  • Biomarkers and Personalized Medicine in IO
  • CAR-T Cell therapy, TCR Based-Cell Therapy
  • Tumor microenvironment
  • Oncolytic Viruses
  • Personalized Cancer Immunotherapy

CSO, Director, VP, Head, Senior Investigator, Manager, Principal Scientist, Team Leader, Group Leaders, Professors, Assistant Professors, Research fellows, PhDs working on

  • Monoclonal and Bispecific Antibodies
  • Cell Therapy
  • Immune Checkpoint Inhibitors

  • Exclusive conference to learn about antibodies, cellular therapy and immune-checkpoint research under one roof
  • Find out new case studies of immune-oncology projects in development
  • Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
  • Explore the latest platforms and technologies on the market for development
  • Discuss the best tool for your research in immune-oncology
  • Share your work and achievements with your industry peers in the Poster Session

CONFERENCE AGENDA

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening remarks from the Chairman

Sophia Karagiannis

Sophia Karagiannis, Professor, Translational Cancer Immunology and Immunotherapy, Kings College London, UK

08:55 - 09:00

NEW ANTIBODY FORMATS & CELLULAR THERAPY

CAR T cells: From bench to bedside, looking toward the future of CAR T treatment

Anat Globerson Levin

Anat Globerson Levin, Director Immunology Lab, R&D, Tel-Aviv Sourasky Medical Center

09:00 - 09:25

The B cell and antibody response in patients with solid tumours

Sophia Karagiannis

Sophia Karagiannis, Professor, Translational Cancer Immunology and Immunotherapy, Kings College London, UK

09:25 - 09:50

CDx strategies to support successful development of Immunotherapies

Patricia McLoughlin

Patricia McLoughlin, Senior Director Business Development, Oncology & Precision Diagnostics, Qiagen

09:50 - 10:20

Morning Refreshments and Poster Presentations | One-to-One Networking Meetings

10:20 - 10:50

From the bench to the market: Thermo Fisher Scientific enables your journey from RnD, to launching a commercial product

James Watson

James Watson , Senior Business Development Manager, Thermo Fischer Scientific, UK

10:50 - 11:20

Development of Next-Generation Antibody Fragment Drug Conjugates Tailored for Gastric Cancer

Mahendra Deonarain

Mahendra Deonarain, Chief Executive and Science Officer, Antikor Biopharma

11:20 - 11:45

Neo-X-Prime™ bispecific antibodies targeting CD40 and tumor antigens

Anette Sundstedt

Anette Sundstedt, Principal Scientist, Alligator Bioscience

11:45 - 12:10

Enhanced Biomarker Discovery and Validation Using TMT® Proteomics

Jessica McDonough

Jessica McDonough, Co-Founder, Attivare Therapeutics

12:35 - 13:05

Anti-glycan mabs are good carriers of drug conjugates

Mireille Vankemmelbeke

Mireille Vankemmelbeke, Principle Scientist, Scancell

12:40 - 13:05

Lunch and Poster Presentations | One-to-One Networking Meetings | Chaired by

Kenji Hashimoto

Kenji Hashimoto, Chief Medical Officer, Crescendo Biologics

13:05 - 14:05

Non-Viral Transfection for Cell Therapy Applications

Valeria Annibaldi

Valeria Annibaldi, Group Leader, R&D Transfection, Lonza

14:05 - 14:20

CAR T-cell immunotherapy of solid tumours: Parallel learning from the clinic and lab

John Maher

John Maher, Scientific Founder and Chief Scientific Officer, Leucid Bio

14:20 - 14:45

Exploiting gamma delta TCR targeting to enable safe and effective cell therapies for solid tumors

Mark Throsby

Mark Throsby, Chief Scientific Officer, Gadeta BV

14:45 - 15:10

T-cell homing in cancer immunotherapy

Ann Ager

Ann Ager, Professor, Cellular Immunity and Immunotherapy, Cardiff University

15:10 - 15:35

Afternoon Refreshments and Poster Presentations | One-to-One Networking Meetings

15:35 - 16:05

Update in development of bispecific Abs

Kenji Hashimoto

Kenji Hashimoto, Chief Medical Officer, Crescendo Biologics

16:05 - 16:30

From One Week to One Day: Take Control of Your Research by Automating Tissue Microarrays, Multiplexing, Whole Slide Scanning and AI Analysis for Enhanced Bioinformatics

Hannaneh Davatgar, Senior Product Specialist and

Hannaneh Davatgar, Senior Product Specialist and, Matthew Cashmore, Senior Product Specialist, Epredia

16:30 - 17:00

Adenosine and TIM3 directly suppress cytolytic killing of tumour target cells via inhibition of cytoskeletal polarisation

Christoph Wuelfing

Christoph Wuelfing, Professor, Immunology, University of Bristol

17:00 - 17:25

Generation of allogeneic CAR T-cell therapies based on a novel γδ T-cell platform

Marc Davies

Marc Davies, VP, CAR Engineering, Leucid Bio

17:25 - 17:50

Systemic immune reaction in lymph nodes adds prognostic information for breast cancer patients

Anita Grigoriadis

Anita Grigoriadis, Reader in Cancer Bioinformatics, King’s College London

17:50 - 18:15

Closing remarks from the Chairman | End of Day 1 followed by Drinks Reception and Networking

Kenji Hashimoto

Kenji Hashimoto, Chief Medical Officer, Crescendo Biologics

18:15 - 18:30

End of Day 1 followed by Drinks Reception and Networking

18:30 - 18:30

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening remarks from the Chairman

08:55 - 09:00

NEW IMMUNE CHECKPOINTS, BIOMARKER AND TUMOUR MICROENVIRONMENT

Keynote: New widely-expressed cancer targets by dissection of successful cancer immunotherapy

Andrew Sewell

Andrew Sewell , Distinguished Research Professor and Wellcome Trust Senior Investigator,, Cardiff University

09:00 - 09:25

Cancer Immunotherapy: accelerating preclinical drug candidate selection using the full advanced human immune system mouse models

Sebastien Tabruyn

Sebastien Tabruyn, Chief Scientific Officer, Transcure Bioservices

09:25 - 09:55

Invasive cancers generate immunosuppressive microenvironments

Victoria Sanz-Moreno

Victoria Sanz-Moreno , Professor, Cancer Cell Biology , Cancer Research UK Barts Centre, UK

09:55 - 10:20

Morning Refreshments and Poster Presentations | One-to-One Networking Meetings

10:20 - 10:50

Enabling the future of precision oncology with comprehensive, unprecedented tumor profiling solutions for both tissue and liquid biopsy

Maik Pruess PhD

Maik Pruess PhD, Senior Field Application Scientist , Personalis Inc

10:50 - 11:20

Therapeutic targeting of a novel family of myeloid checkpoint inhibitors

Ali Roghanian

Ali Roghanian, PhD, FHEA | Associate Prof in Cancer Immunotherapy | BM Research Project Deputy Module Leader, Centre for Cancer Immunology | Faculty of Medicine | University of Southampton

11:20 - 11:45

The metastatic niche – De-construct the different cellular components within a tumour to identify new therapeutic targets

Luigi Ombrato

Luigi Ombrato, Group Leader, Barts Cancer Institute

11:45 - 12:10

Engineering strategies for improving adoptive T-cell therapy of cancer

Melita Irving

Melita Irving, Group Leader, Human integrated tumor immunology discovery engine (Hi-TIDe), Ludwig Institute for Cancer Research

12:10 - 12:35

Potential of vaccines for refractory patients

John Maudsley

John Maudsley, CEO, Cancer Vaccines Ltd

12:35 - 13:00

Lunch and Poster Presentations | One-to-One Networking Meetings

13:00 - 14:00

Using Metabolimics to Synchronize and optimize Immune-Oncology Strategies

Brian Keppler

Brian Keppler , Director, Discovery and Translational Sciences, Metabolon

14:00 - 14:30

How Biomarker multi-omics approach from Veracyte brings value to Biopharma drug development programs?

Corinne Danan

Corinne Danan, General Manager, Biopharma, Veracyte

14:30 - 15:00

Adressing Tumor Heterogeneity with Oncolytic Molecules - an unsolved issue in Cancer Immunotherapy

OR

OR, CEO, Lytix Biopharma

15:00 - 15:25

Small activating RNA from concept to Phase 2 clinical trials

Nagy Habib

Nagy Habib, Founder and Head of R&D, MiNA Therapeutics

15:25 - 15:50

End of Conference

16:00 - 16:00

Closing remarks from the Chairman | End of Conference

16:15 - 16:15

SPEAKERS

Andrew Sewell

Andrew Sewell

Distinguished Research Professor and Wellcome Trust Senior Investigator,, Cardiff University

Corinne Danan

Corinne Danan

General Manager, Biopharma, Veracyte

Mireille Vankemmelbeke

Mireille Vankemmelbeke

Principle Scientist, Scancell

Brian Keppler

Brian Keppler

Director, Discovery and Translational Sciences, Metabolon

Sebastien Tabruyn

Sebastien Tabruyn

Chief Scientific Officer, Transcure Bioservices

Jessica McDonough

Jessica McDonough

Co-Founder, Attivare Therapeutics

Matthew Cashmore

Matthew Cashmore

Senior Product Specialist, Epredia

Hannaneh Davatgar

Hannaneh Davatgar

Senior Product Specialist, Epredia

Sophia Karagiannis

Sophia Karagiannis

Professor, Translational Cancer Immunology and Immunotherapy, Kings College London, UK

Christoph Wuelfing

Christoph Wuelfing

Professor, Immunology, University of Bristol

Marc Davies

Marc Davies

VP, CAR Engineering, Leucid Bio

Patricia McLoughlin

Patricia McLoughlin

Senior Director Business Development, Oncology & Precision Diagnostics, Qiagen

Anita Grigoriadis

Anita Grigoriadis

Reader in Cancer Bioinformatics, King’s College London

Valeria Annibaldi

Valeria Annibaldi

Group Leader, R&D Transfection, Lonza

Kenji Hashimoto

Kenji Hashimoto

Chief Medical Officer, Crescendo Biologics

Mahendra Deonarain

Mahendra Deonarain

Chief Executive and Science Officer, Antikor Biopharma

Ann Ager

Ann Ager

Professor, Cellular Immunity and Immunotherapy, Cardiff University

Mark Throsby

Mark Throsby

Chief Scientific Officer, Gadeta BV

OR

OR

CEO, Lytix Biopharma

Anat Globerson Levin

Anat Globerson Levin

Director Immunology Lab, R&D, Tel-Aviv Sourasky Medical Center

Luigi Ombrato

Luigi Ombrato

Group Leader, Barts Cancer Institute

Anette Sundstedt

Anette Sundstedt

Principal Scientist, Alligator Bioscience

Ali Roghanian

Ali Roghanian

PhD, FHEA | Associate Prof in Cancer Immunotherapy | BM Research Project Deputy Module Leader, Centre for Cancer Immunology | Faculty of Medicine | University of Southampton

Victoria Sanz-Moreno

Victoria Sanz-Moreno

Professor, Cancer Cell Biology , Cancer Research UK Barts Centre, UK

Nagy Habib

Nagy Habib

Founder and Head of R&D, MiNA Therapeutics

ENQUIRE NOW

SPONSORS

PARTNERS

LOCATION

Venue

ILEC Conference Center and IBIS London Earls Court, 47 Lillie Road, London, SW6 1UD

PAST EVENT GALLERY